GOLZAYDA
Live / Applied — First extension granted (statement of use) (as of 24 Feb 2026)
What this means for you
Not registered yet, but its 10 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98641585
- Mark type
- Stylized text
- Filed
- 10 Jul 2024
- Published for opposition
- 10 Jun 2025
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.
Owner
- Celgene Corporation, Princeton, NJ, US
- Celgene Corporation, Princeton, NJ, US
Prosecution history
- 24 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Feb 2026 — SOU EXTENSION 1 GRANTED
- 24 Feb 2026 — SOU EXTENSION 1 FILED
- 24 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 30 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 10 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Jun 2025 — PUBLISHED FOR OPPOSITION
- 04 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 May 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 03 Feb 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Feb 2025 — NON-FINAL ACTION E-MAILED
- 03 Feb 2025 — NON-FINAL ACTION WRITTEN